Donna Haseley

1 month ago | insidehealthpolicy.com | Donna Haseley

In just 100 days the U.S. health care system has been turned on its head, leaving industry stakeholders who thrive on certainty reeling from the ensuing regulatory unpredictability and wondering whether the system they’ve navigated for decades will return.

1 month ago | insidehealthpolicy.com | Maaisha Osman |Donna Haseley

HHS Secretary Robert F. Kennedy Jr. doubled down on his calls for a radical transformation of government health agencies, telling FDA staff Friday ( April 11) the agency has become a “sock puppet” of the industries it regulates and urging them to resist the “deep state,” according to a recording obtained by media outlets, capping off a tumultuous week that included a key public health group’s call for Kennedy’s resignation and a duo of Journal of the American Medical Association...

Feb 18, 2025 | insidehealthpolicy.com | Jessica Karins |Amy Lotven |Christian Robles |Donna Haseley

The Trump administration fired thousands probationary employees at HHS and its subagencies over the weekend apparently without regard to the programs they worked on, adding to widespread uncertainty among health care stakeholders about how the new administration will handle everything from FDA user fees to the administration of Medicare and Medicaid. The cuts were condemned by former agency heads from the Biden administration Monday (Feb. 17).

Feb 12, 2025 | insidehealthpolicy.com | Donna Haseley |Maaisha Osman

President Donald Trump again referenced a desire to stop U.S. consumers from paying more for drugs than people overseas, specifically mentioning high U.S. prices for GLP-1s, in an interview during the Super Bowl that adds to confusion on what drug pricing policies he has in store. In the Monday (Feb. 10) interview, Trump promised to fix the situation without providing details other than a reference to his earlier support for drug imports, and he mentioned he might slap tariffs on...

Jan 17, 2025 | insidehealthpolicy.com | Gabrielle Wanneh |Donna Haseley

The Biden administration on Friday (Jan. 17) announced the 15 drugs -- which include GLP-1 diabetes drugs, cancer and asthma treatments -- it has selected for the next round of Medicare price negotiation, unveiling the list before the Feb. 1 deadline in an apparent attempt to shape the next round of price talks before the Trump administration takes over Monday (Jan. 20). The inclusion of GLP-1s on the list is significant because President Joe Biden’s CMS has proposed Medicare and...